| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
PALO ALTO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, ", Scilex", ))))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC:SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a master distributor agreement with Farouk, Maamoun Tamer & Co. for the distribution of ZTlido® in Kingdom of Saudi Arabia.
ZTlido® is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN). ZTlido® was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.
"We are pleased to announce the master distributor agreement with Scilex to bring to the people of KSA a non-opioid alternative for pain management due to the risk of addiction associated with the prolonged use of prescription opioids," said Dr. Yasser Khattab, Chief Executive Officer of Tamer Healthcare.
"We aim to be vertically integrated, including having the ability to conduct future research & development in tandem with partner companies such as Scilex," added Dr. Ahmed Mousa, Business Development Head at Tamer Healthcare.
"This agreement represents another critical milestone towards bringing our innovative non-opioid pain management medicines to people around the world," said Jaisim Shah, President and Chief Executive Officer of Scilex.
